Dova's thrombocytopenia drug gets its first approval from FDA

FDA approved Doptelet avatrombopag from the AkaRx Inc. subsidiary of Dova Pharmaceuticals Inc. (NASDAQ:DOVA) to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. The agency said it is the first drug approved in the indication.

Dova plans to launch Doptelet in June, at which time it will disclose pricing details...